OPENDEL
LIVE

Serial Number

79374942

Owner

HitGen Inc.

Filing Date

Apr 19, 2023

Add to watchlist:

No watchlists yet
View on USPTO

OPENDEL Trademark

Serial Number: 79374942 • Registration: 7376720

OPENDEL is a trademark filed by HitGen Inc. on April 19, 2023. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

HitGen Inc. (6 trademarks)

Floor 3, Building 1, No. 88, Keyuan South Road,

Entity Type: 03

Trademark Details

Filing Date

April 19, 2023

Registration Date

May 7, 2024

Published for Opposition

February 20, 2024

Goods & Services

Chemico-pharmaceutical preparations for the treatment of diseases caused by bacteria; drugs for medical purposes, namely, pharmaceutical preparations for treating neurological disease, muscular disease, ischemic disease, renal disease, cancer; biological preparations for medical purposes for the treatment of tumors, cancer, precancerous lesions, chronic infections, autoimmune diseases, fatty liver, inflammatory bowel disease, cervical neoplasia, viral infections, metabolic diseases, immunodeficiency, osteoarthritis, thyroid disease, glycometabolism disease, bone metabolic disease, gonad disease, kidney disease, cardiovascular disease, hepatic fibrosis, anemia, inflammation diseases, hepatitis disease, epstein-barr (eb) viruses, hormonal diseases, allergic, immune disorder, torch infections and immunoglobulin diseases; antibiotics; medicines for human purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; medicines made of chinese traditional medicinal herbs; biochemical drugs for the treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system, inflammatory disorders, dermatological conditions, oncological diseases, blood diseases, connective tissue disorders, ophthalmic diseases, and gastroenterological disorders; lotions for pharmaceutical purposes being medicated lotions for treating dermatological conditions; chemical preparations for pharmaceutical purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; allergy tablets; antibiotic tablets; vitamin tablets; effervescent vitamin tablets

Chemical preparations for scientific purposes, other than for medical or veterinary use; chemical substances for analyses in laboratories, other than for medical or veterinary purposes; chemical reagents, other than for medical or veterinary purposes; biochemical preparations for scientific purposes; buffer solutions for use in analytical chemistry; biochemical catalysts

Technological research in the field of medical and healthcare; conducting technical project studies for determining the feasibility of new technologies; research and development of new products for others; scientific laboratory services; product quality evaluation; quality evaluation services for the medical and anesthesia industries; chemical research; chemistry consultation; chemical analysis; bacteriological research; biological research

Filing History

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jan 10, 2025 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Dec 22, 2024 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Dec 19, 2024 OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Dec 19, 2024 OPNR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jun 6, 2024 FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jun 6, 2024 FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jun 6, 2024 FICR
REGISTERED-PRINCIPAL REGISTER
May 7, 2024 R.PR
NOTIFICATION PROCESSED BY IB
Mar 4, 2024 GPNX
PUBLISHED FOR OPPOSITION
Feb 20, 2024 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Feb 14, 2024 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Feb 14, 2024 OP2R
NOTICE OF PUBLICATION
Jan 31, 2024 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 17, 2024 CNSA
ASSIGNED TO EXAMINER
Jan 17, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Aug 8, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 4, 2023 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Aug 3, 2023 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 20, 2023 REPR